- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.03. | Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating | 1 | Investing.com | ||
| 11.03. | Artiva Biotherapeutics: Cantor Fitzgerald bekräftigt "Overweight"-Rating | 4 | Investing.com Deutsch | ||
| 10.03. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights | 589 | GlobeNewswire (Europe) | Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial... ► Artikel lesen | |
| 10.03. | Artiva Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.02. | Artiva Biotherapeutics Names Thad Huston CFO | 3 | RTTNews | ||
| 24.02. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant | 327 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible... ► Artikel lesen | |
| 19.02. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology ... | 1 | GlobeNewswire (USA) | ||
| 12.12.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.11.25 | Artiva BioTherapeutics GAAP EPS of -$0.88 | 3 | Seeking Alpha | ||
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease | 264 | GlobeNewswire (Europe) | 32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 200 | GlobeNewswire (Europe) | Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®... ► Artikel lesen | |
| 12.11.25 | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.10.25 | Cantor Fitzgerald reiterates Overweight rating on Artiva Biotherapeutics stock | 19 | Investing.com | ||
| 16.10.25 | Rheumatoide Arthritis: Artiva erhält FDA Fast-Track-Status für Zelltherapie AlloNK | 5 | Investing.com Deutsch | ||
| 16.10.25 | Artiva's AlloNK receives FDA Fast Track status for rheumatoid arthritis | 3 | Investing.com | ||
| 16.10.25 | Artiva Biotherapeutics stock soars after FDA Fast Track designation | 2 | Investing.com | ||
| 16.10.25 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | 432 | GlobeNewswire (Europe) | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 74,50 | -1,84 % | BioNTech Aktie: Panik war gestern! Gründer weg, Kurs im Keller und trotzdem könnte es jetzt ein gutes Investment sein! | © Foto: von Mathurin NAPOLY / matnapo auf Unsplash (Symbolbild)Die Nachricht schlug ein wie eine Bombe: Das Gründerduo Ugur Sahin und Özlem Türeci verlässt BioNTech. Die Reaktion an der Börse war ein... ► Artikel lesen | |
| AMGEN | 306,75 | -0,11 % | Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375 | ||
| NOVAVAX | 7,791 | -0,93 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 165,30 | -0,33 % | Biogen Inc.: Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity | In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,210 | -4,98 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,423 | -9,89 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 10,710 | -7,19 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 36,800 | -7,54 % | Tempus AI Enters Collaboration With Daiichi Sankyo | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Tempus AI announced a strategic collaboration with Daiichi Sankyo (4568.T) for accelerating the clinical development and differentiation of an antibody drug... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,584 | +3,20 % | BioCryst strebt Milliardenumsatz an und stärkt HAE-Portfolio mit Navenibart | ||
| BIOMARIN PHARMACEUTICAL | 48,400 | +0,39 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,170 | -4,17 % | SRPT Stock Surges on Promising Early Results From siRNA Programs | ||
| EXELIXIS | 36,260 | +2,34 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,190 | +1,17 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,060 | +10,76 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 26.03.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 26.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 26.03.2026.ISIN NameCA2568277834 DOLLY... ► Artikel lesen |
ARTIVA BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,840 Euro und damit -6,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.